DrugDev, Citeline Partner to Integrate Data

May 11, 2017

Philadelphia, PA and New York, NY – DrugDev and Citeline, part of Informa’s Pharma Intelligence vertical, announced today that the two companies have integrated data from Citeline’s Trialtrove and Sitetrove intelligence platforms with the DrugDev Spark unified clinical operations suite. Indexing information captured by Citeline on more than 390,000 investigators across over 265,000 trials in more than 170 countries to the industry-standard DrugDev Golden Number adds significantly to the amount of information available for study planning and site identification through DrugDev Spark.
 
By incorporating data from Citeline into DrugDev Spark, mutual Citeline and DrugDev biopharma clients can now easily and efficiently identify the ideal sites at which to conduct their clinical trials. In addition, clients using DrugDev Spark will be able to seamlessly move from study planning and site identification to other proven solutions such as site activation, site payments, eConsent, learning management, document exchange, site engagement and more.
 
This significant collaboration allows Informa’s Pharma Intelligence vertical’s clients who subscribe to both Trialtrove and Sitetrove system via XML feed and who are also clients of DrugDev to access a broader range of data sources. By integrating key Citeline data components into the DrugDev Spark study planning and site identification toolset, users can simplify the once arduous task of having to utilize multiple resources to research clinical trial investigators at high performing sites for their own clinical studies.

Citeline clients participating in the Investigator Databank or TransCelerate’s Investigator Registry collaboration, for example, will now have the ability to see data from: online profiles, their own CTMS, other member’s CTMS, the DrugDev network, clinicaltrials.gov, and Citeline’s Trialtrove and Sitetrove.
 
“We are excited to be working with DrugDev for our mutual clients’ benefit in improving the speed and success of clinical drug development. Our customers need data, together with technology, to deliver new and innovative drugs into the pharmaceutical market. We look forward to furthering the relationship with DrugDev to assist our customers in achieving that goal,’ said Linda Blackerby, President of Informa Pharma Intelligence.
 
Combining all available data assets into one single view increases the breadth of evidence available to encompass data from both public and private domains. This in turn enables both faster and better decision-making by considering all information in a single query as opposed to the current practice of running queries in multiple systems and having to consolidate results to understand the full landscape for the study.
 
Elisa Cascade, President, Data Solutions at DrugDev, explained, “Informa has a reputation for excellence in pharma intelligence among the global pharma community. We are excited to partner with Informa because we are committed to making it easier and more expedient for pharma and biotech organizations to conduct more clinical trials. By integrating data in one trusted location, we can now simplify the evidence-based planning and site identification process for our customers through access to a single integrated view of data from all available sources – enabling sponsors to make better site selection decisions, faster.”